1. Soluble immune markers in the different phases of chronic hepatitis B virus infection
- Author
-
Steffen B. Wiegand, Bastian Beggel, Anika Wranke, Elmira Aliabadi, Jerzy Jaroszewicz, Cheng-Jian Xu, Yang Li, Michael P. Manns, Thomas Lengauer, Heiner Wedemeyer, Anke R. M. Kraft, Christine S. Falk, and Markus Cornberg
- Subjects
Medicine ,Science - Abstract
Abstract Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by immune markers are not considered in this definition. We aimed to study soluble immune markers and their distribution in different phases of chronic HBV infection. In this cross-sectional retrospective study, we investigated a panel of 14 soluble immune markers (SIM) including CXCL10 in 333 patients with chronic HBV infection. In a small cohort of HBeAg positive patients we analyzed SIM before and after HBeAg seroconversion and compared seroconverters to patients with unknown outcome. Significant differences were documented in the levels of several SIM between the four phases of chronic HBV infection. The most pronounced difference among all investigated SIM was observed for CXCL10 concentrations with highest levels in patients with hepatitis. TGF-β and IL-17 revealed different levels between HBeAg negative patients. HBeAg positive patients with HBeAg seroconversion presented higher amounts of IL-12 before seroconversion compared to HBeAg positive patients with unknown follow up. SIM such as CXCL10 but also IL-12, TGF-β and IL-17 may be useful markers to further characterize the phase of chronic HBV infection.
- Published
- 2019
- Full Text
- View/download PDF